The National Cancer Institute (NCI) awarded a $103,948 Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research, a non-profit cancer research organization located in New York. The funding will support a research project titled "Identifying and Targeting Drivers of Impaired Translation in Tumor-Infiltrating CD8+ T-Cells." The research aims to investigate how amino acid availability in the tumor microenvironment limits the effector function of tumor-infiltrating T-cells, and explore the role of non-coding RNAs in translational suppression during T-cell exhaustion. The goal is to elucidate the mechanisms underlying T-cell dysfunction and leverage these insights to enhance the efficacy of immune checkpoint blockade cancer therapies. The grant has an award period from September 1, 2024 to August 31, 2026.
Generated 3/4/25, 6:14 AM